glucosamine has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Fátima Cobre, A; Fachi, MM; Lobo Borba, HH; Pontarolo, R; Stremel, DP; Surek, M; Tonin, FS | 1 |
| Bigioni, I; De Berardis, B; Marchetti, M; Mariano, A; Scotto d'Abusco, A; Superti, F | 1 |
| Chen, Q; Deng, Y; Dong, Y; Duan, X; Jin, G; Li, Y; Qi, Q; Qin, C; Wang, J; Wang, K; Zhang, R; Zheng, A | 1 |
3 other study(ies) available for glucosamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning.
Topics: Biomarkers; Chromatography, Liquid; COVID-19; COVID-19 Testing; Glucosamine; Humans; Machine Learning; Ornithine; Phosphates; SARS-CoV-2; Tandem Mass Spectrometry; Thymine | 2022 |
In Vitro Antiviral and Anti-Inflammatory Activities of
Topics: Acetylglucosamine; Adenoviridae; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; Glucosamine; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Pneumonia; Respiratory Tract Infections; SARS-CoV-2; Virus Diseases | 2023 |
Oral administration of D-glucosamine confers broad-spectrum protection against human coronaviruses including SARS-CoV-2.
Topics: Administration, Oral; COVID-19; Glucosamine; Humans; SARS-CoV-2 | 2023 |